Abstract:This review comprehensively summarizes the advances in research for fibrosis. It emphasizes organ‐specific profibrotic cell types and molecular mechanisms of fibrosis, especially in the kidney, liver, lung, and heart. The authors highlight the advanced antifibrotic small molecule drugs and cellular therapies for fibrosis. These findings have critical implications for further research and clinical translation of medicine. As the final stage of disease‐related tissue injury and repair, fibrosis is characterized by excessive accumulation of the extracellular matrix. Unrestricted accumulation of stromal cells and matrix during fibrosis impairs the structure and function of organs, ultimately leading to organ failure. The major etiology of fibrosis is an injury caused by genetic heterogeneity, trauma, virus infection, alcohol, mechanical stimuli, and drug. Persistent abnormal activation of "quiescent" fibroblasts that interact with or do not interact with the immune system via complicated signaling cascades, in which parenchymal cells are also triggered, is identified as the main mechanism involved in the initiation and progression of fibrosis. Although the mechanisms of fibrosis are still largely unknown, multiple therapeutic strategies targeting identified molecular mechanisms have greatly attenuated fibrotic lesions in clinical trials. In this review, the organ‐specific molecular mechanisms of fibrosis is systematically summarized, including cardiac fibrosis, hepatic fibrosis, renal fibrosis, and pulmonary fibrosis. Some important signaling pathways associated with fibrosis are also introduced. Finally, the current antifibrotic strategies based on therapeutic targets and clinical trials are discussed. A comprehensive interpretation of the current mechanisms and therapeutic strategies targeting fibrosis will provide the fundamental theoretical basis not only for fibrosis but also for the development of antifibrotic therapies.

Epigenetic Regulation in Fibrosis Progress.

Epigenetics As a Versatile Regulator of Fibrosis

Epigenetics and Fibrosis

Epigenetic modifications in fibrotic diseases: implications for pathogenesis and pharmacological targets.

Epigenetic Modifications in Fibrotic Diseases: Implications for Pathogenesis and Pharmacological Targets

Epigenetic signatures in cardiac fibrosis, special emphasis on DNA methylation and histone modification

Epigenetic Regulation of EMP/EMT-Dependent Fibrosis

Epigenetic Regulation of Fibroblasts and Crosstalk between Cardiomyocytes and Non-Myocyte Cells in Cardiac Fibrosis

New aspects of the epigenetic regulation of EMT related to pulmonary fibrosis

m6A epitranscriptomic and epigenetic crosstalk in cardiac fibrosis

The Epigenetic Feedback Loop Between DNA Methylation and Micrornas in Fibrotic Disease with an Emphasis on DNA Methyltransferases.

Targeting Fibrosis: From Molecular Mechanisms to Advanced Therapies

Glycolytic reprogramming in organ fibrosis: New dynamics of the epigenetic landscape

Emerging role of m6A modification in fibrotic diseases and its potential therapeutic effect

Epithelial-mesenchymal Transition in Organ Fibrosis Development: Current Understanding and Treatment Strategies

MicroRNAs and the Regulation of Fibrosis

Current concepts in the epigenetic regulation of cardiac fibrosis

Epigenetic signatures in cardiac fibrosis: Focusing on noncoding RNA regulators as the gatekeepers of cardiac fibroblast identity

[Epigenetics and Liver Fibrogenesis].

MicroRNAs-mediated Epithelial-Mesenchymal Transition in Fibrotic Diseases

Fibroblast Diversity and Epigenetic Regulation in Cardiac Fibrosis